Depemokimab

德莫奇单抗

Report date: 2026/05/25 20:02:40

Base Information

Drug NameDepemokimab
Drug Alias NameExdensur易适来GSK-3511294GSK3511294GSK-294 +[7] 
ClassificationBiologics > Protein drugs > Immunoglobulin > Antibody > Monoclonal antibody > Monoclonal antibody humanized
Mechanisms of ActionAnti-Interleukin-5
TargetsInterleukin-5
Therapy Area/IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Eosinophilic AsthmaHypereosinophilic Syndrome +[10] 
Global Approved IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Eosinophilic AsthmaNasal Polyps +[5] 
Approved Indications in ChinaEosinophilic Asthma
Original Approved Country/TerritoryUnited Kingdom
Original Approved Date2025/12/15
Country/TerritoryCzechiaBelgiumBulgaria +[44] 
CombinationsNo
Global Highest StatusApproved
Highest Status in ChinaApproved
Originator CompaniesGlaxosmithkline Plc
China Registration ClassN/A

Develop Information

Active CompaniesGlaxosmithkline Trading Services LtdGlaxosmithkline PlcGlaxosmithkline (Ireland) Ltd +[8] 
Inactive CompaniesN/A
Active IndicationsChronic rhinosinusitis with nasal polyps (CRSwNP)Eosinophilic AsthmaHypereosinophilic Syndrome +[10] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A